Cargando…

WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?

Docetaxel improved the outcome of patients with mCSPC and became standard of care after CHAARTED, STAMPEDE arm C and GETUG-AFU 15 clinical trials and after subsequent meta-analysis. Patients with high-volume (CHAARTED definition) and high-risk (LATITUDE definition) disease, who have good performance...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamulin, Marija, Bebek, Marko, Gnjidic, Milena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693549/
https://www.ncbi.nlm.nih.gov/pubmed/34975202
http://dx.doi.org/10.20471/acc.2019.58.s2.12
_version_ 1784619163991408640
author Gamulin, Marija
Bebek, Marko
Gnjidic, Milena
author_facet Gamulin, Marija
Bebek, Marko
Gnjidic, Milena
author_sort Gamulin, Marija
collection PubMed
description Docetaxel improved the outcome of patients with mCSPC and became standard of care after CHAARTED, STAMPEDE arm C and GETUG-AFU 15 clinical trials and after subsequent meta-analysis. Patients with high-volume (CHAARTED definition) and high-risk (LATITUDE definition) disease, who have good performance status and are fit for chemotherapy, seem to benefit the most from addition of docetaxel to the androgen deprivation therapy. Results from TITAN trial with apalutamide showed the activity in the same setting. However, predictive biomarkers are still lacking. We have direct evidence of overall survival benefit from abiraterone, apalutamide and enzalutamide for patients with high-volume disease who are not fit for chemotherapy, as well as for patients with low-volume disease. Clinical trials will show is there place for triple therapy in clinical practice. Before obtaining the results of new clinical trial results, physicians should base their treatment decision on risks and benefits of each current approach and consider the patient´s other health issues such as access, costs, patient and patient´s preferences.
format Online
Article
Text
id pubmed-8693549
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb
record_format MEDLINE/PubMed
spelling pubmed-86935492021-12-30 WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)? Gamulin, Marija Bebek, Marko Gnjidic, Milena Acta Clin Croat Professional Papers Docetaxel improved the outcome of patients with mCSPC and became standard of care after CHAARTED, STAMPEDE arm C and GETUG-AFU 15 clinical trials and after subsequent meta-analysis. Patients with high-volume (CHAARTED definition) and high-risk (LATITUDE definition) disease, who have good performance status and are fit for chemotherapy, seem to benefit the most from addition of docetaxel to the androgen deprivation therapy. Results from TITAN trial with apalutamide showed the activity in the same setting. However, predictive biomarkers are still lacking. We have direct evidence of overall survival benefit from abiraterone, apalutamide and enzalutamide for patients with high-volume disease who are not fit for chemotherapy, as well as for patients with low-volume disease. Clinical trials will show is there place for triple therapy in clinical practice. Before obtaining the results of new clinical trial results, physicians should base their treatment decision on risks and benefits of each current approach and consider the patient´s other health issues such as access, costs, patient and patient´s preferences. Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019-11 /pmc/articles/PMC8693549/ /pubmed/34975202 http://dx.doi.org/10.20471/acc.2019.58.s2.12 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Professional Papers
Gamulin, Marija
Bebek, Marko
Gnjidic, Milena
WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
title WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
title_full WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
title_fullStr WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
title_full_unstemmed WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
title_short WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
title_sort which patients will benefit most from docetaxel addition to androgen deprivation therapy (adt) in metastatic castrate-sensitive prostate cancer (mcspc)?
topic Professional Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693549/
https://www.ncbi.nlm.nih.gov/pubmed/34975202
http://dx.doi.org/10.20471/acc.2019.58.s2.12
work_keys_str_mv AT gamulinmarija whichpatientswillbenefitmostfromdocetaxeladditiontoandrogendeprivationtherapyadtinmetastaticcastratesensitiveprostatecancermcspc
AT bebekmarko whichpatientswillbenefitmostfromdocetaxeladditiontoandrogendeprivationtherapyadtinmetastaticcastratesensitiveprostatecancermcspc
AT gnjidicmilena whichpatientswillbenefitmostfromdocetaxeladditiontoandrogendeprivationtherapyadtinmetastaticcastratesensitiveprostatecancermcspc